Tags: Apoe
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
announcements
May 10, 2019
$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
blog
June 20, 2018
Gene Therapy, A New Frontier in Alzheimer’s
Dr. Ron Crystal and his team at Weill Cornell developed a gene therapy to replace APOE4 with APOE2, which would significantly lower Alzheimer's risk.
blog
September 24, 2014
New Drug Targets Are Highlight of Alzheimer’s Conference
Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers.
blog
August 18, 2014
Drugs to “Fix” the APOE4 Gene May Be Safe
New research reveals that a person without the APOE gene—which influences Alzheimer’s risk—can function normally, paving the way for gene therapies.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).